Meda rejects revised offer from Mylan

April 28, 2014 by The Associated Press

Swedish pharmaceutical company Meda says it has rejected another offer from U.S. generic drugmaker Mylan Inc.

Meda says its board decided to reject a revised Mylan proposal because the deal lacks support from Meda's largest shareholder, which the did not name in a brief statement. It also says the board turned down the offer due to a strong belief in Meda's potential as a stand-alone company.

Meda says all contact between the companies has ended with no further actions. The Swedish company also rebuffed an approach from Mylan earlier this month.

Mylan representatives did not immediately return a call seeking comment.

Meda's products include the eczema treatment Elidel and the antiseptic Betadine. It says its products are sold in more than 120 countries.

Mylan is based in Canonsburg, Pa.

Explore further: Connexins: Providing protection to cells destroyed in Type 1 diabetes

Related Stories

Generic versions of plavix approved

May 18, 2012

(HealthDay) -- The first generic versions of Plavix (clopidogrel bisulfate) have been approved by the U.S. Food and Drug Administration.

US drug firm Mylan to buy Indian firm for $1.6 bn

February 27, 2013

US generic drugs specialist Mylan said Thursday it would buy a unit of India's pharma firm Strides Arcolab for $1.6 billion, boosting its presence in the high-growth injectable drugs market.

Indian drugs group eyes $5 bn Swedish deal

May 31, 2013

Indian group Sun Pharmaceutical Industries is in talks to buy leading Swedish drugmaker Meda AB in what could result in a $5 billion takeover, the Wall Street Journal reported on Friday.

US drugs firm Mylan completes $1.75 bln India buyout

December 5, 2013

US generic drug specialist Mylan said Thursday it had completed its $1.75 billion acquisition of a unit of India's Strides Arcolab, boosting its presence in the high-growth injectable drugs market.

Recommended for you

FDA bolsters warnings about class of antibiotics

July 26, 2016

(HealthDay)—The U.S. Food and Drug Administration announced Tuesday that it's strengthening label warnings on a class of antibiotics called fluoroquinolones because the drugs can lead to disabling side effects, including ...

Why kicking the opioid habit can be so tough

July 20, 2016

(HealthDay)—He was 26, a specialist fifth class with the U.S. Army, and stationed abroad, when an accident on the German autobahn sent him careening through the windshield of his car.

New research shows vaccine protection against Zika virus

June 28, 2016

The rapid development of a safe and effective vaccine to prevent the Zika virus (ZIKV) is a global priority, as infection in pregnant women has been shown to lead to fetal microcephaly and other major birth defects. The World ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.